VASCULITIS TREATMENT MARKET ANALYSIS

Market News

Key Developments

Major players in the market are focused on approval and launch of novel therapeutics intended for the treatment of various types of vasculitis. For instance, in July 2019, Pfizer Inc. announced that its RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan (rituximab), intended for the treatment of adult patients with microscopic polyangiitis, received the U.S. Food and Drug Administration (FDA) approval.

Major institutes and universities are focused on R&D activities related to the treatment of vasculitis. For instance, in August 2019, researchers from Hospital El Bierzo and Burgos University Hospital, Spain, suggested adoption of disease management based on individual patient characteristics and levels of disease severity for the treatment of vasculitis.

Similarly, in August 2019, researchers from Osaka University Graduate School of Medicine, Japan found that intravenous immunoglobulin was associated with rapid improvements in disease activity and the related biomarkers in patients with active ANCA-associated vasculitis.